Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of RV521 for RSV upper respiratory tract infection in adult hematopoietic cell transplant recipients
MOH_2020-09-22_009168Phase 2Recruiting
- Sponsor
- ReViral
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing RV521 with Placebo (2 arms). Primary endpoints: Proportion of subjects without lower respiratory tract complications during the study period and Time-weighted average change in RSV viral load. Started Jul 2020; status: recruiting.
02
Drugs
sisunatovir
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on MOH_2020-09-22_009168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-09-22_009168.